Potentiation effects of (±)huprine X, a new acetylcholinesterase inhibitor, on nicotinic receptors in rat cortical synaptosomes

Neuropharmacology

Volumn 46, Issue 1, 2004, Pages 95-102

  Roman, S ^a   Badia, A ^a   Camps, P ^b   Clos, M V ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

( )Huprine X; Acetylcholinesterase inhibitors; Galantamine; Nicotinic receptors; Physostigmine; Synaptosomes

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; GALANTAMINE; HUPRINE X; MECAMYLAMINE; NICOTINIC RECEPTOR; PHYSOSTIGMINE; TRITIUM; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; NICOTINIC RECEPTOR BLOCKING AGENT;

ACETYLCHOLINE RELEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN SYNAPTOSOME; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ISOTOPE LABELING; MALE; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; RAT; STIMULATION; ANIMAL; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; METABOLISM; SPRAGUE DAWLEY RAT; SYNAPTOSOME;

ACETYLCHOLINE; AMINOQUINOLINES; ANIMALS; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GALANTAMINE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; MALE; MECAMYLAMINE; NICOTINIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; SYNAPTOSOMES;

EID: 0344256513     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2003.08.005     Document Type: Article

References (32)

1. Alkondon M., Pereira E.F., Cortes W.S., Maelicke A., Albuquerque E.X. Choline is a selective agonist of α7 nicotinic acetylcholine receptors in rat brain neurons. European Journal of Neuroscience. 9:1997;2742.
2. Alkondon M., Pereira E.F., Eisenberg H.M., Albuquerque E.X. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. Journal of Neuroscience. 19:1999;2705.
3. Badia A., Baños J.E., Camps P. Synthesis and evaluation of tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. Bioorganics and Medicinal Chemistry. 6:1998;427-440.
4. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1984;408-417.
5. Benzi G., Moretti A. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? European Journal of Pharmacology. 346:1998;1-13.
6. Birdsall N.J.M., Nathanson N.M. Muscarinic receptors: it's a knockout. Trends in Pharmacological Sciences. 22:2001;215-219.
7. Camps P., El Achab R., Morral J., Muñoz-Torrero D., Badia A., Baños J.E., Vivas N.M., Barril X., Orozco M., Luque F.J. New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. Journal Medical Chemistry. 43:2000;4657-4666.
8. Cheng D.H., Tang X.C. Comparative studies of Huperzine A, E2020 and tacrine on behavior and cholinesterase activities. Pharmacological Biochemistry Behavior. 60:1998;377-386.
9. DeKosky S.T., López O.L. Neurobiología y biología molecular de la enfermedad de Alzheimer. Revista Neurológica. 27:1998;s.
10. García-Sanz A., Badia A., Clos M.V. Superfusion of synaptosomes to study presynaptic mechanisms involved in neurotransmitter release from rat brain. Brain Research Protocols. 7:2001;94-102.
11. Giacobini E. Invited review cholinesterase inhibitor for Alzheimer's disease therapy: from tacrine to future applications. Neurochemistry International. 32:1998;413-419.
12. Gray E.G., Whittaker V.P. The isolation of nerve endings from brain: an electron-microscopic study of cell fragments derived by homogenization and centrifugation. Journal of Anatomy. 96:1962;79-88.
13. Johnson J.W., Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 325:1987;529-531.
14. Maelicke A., Albuquerque E.X. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. European Journal of Pharmacology. 393:2000;165-170.
15. Maelicke A., Schrattenholz A., Samochocki M., Radina M., Albuquerque E.X. Allosterically potentiating ligands of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Behavioural Brain Research. 113:2000;199-206.
16. 2+ ions in their function and desensitization. Neurochemistry International. 34:1999;319-328.
17. Marchi M., Raiteri M. Nicotinic autoreceptors mediating enhancement of acetylcholine release become operative in conditions of "impaired" cholinergic presynaptic function. Journal of Neurochemistry. 67:1996;1974-1981.
18. Martín-Ruiz C.M., Court J.A., Molnar E., Lee M. α4 but not α3 and α7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. Journal of Neurochemistry. 73:1999;1635-1640.
19. Mayer M.L., Vyklicky L. Jr., Westbrook G.L. Modulation of excitatory amino acid receptors by groups IIB metal cations in cultured mouse hippocampal neurons. Journal of Physiology. 415:1989;329-350.
20. Nilsson L., Adem A., Hardy J., Winblad B., Nordberg A. Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors? Journal of Neuronal Transmission. 70:1987;357-368.
21. Raiteri M., Angelini F. A simple apparatus for studying the release of neurotransmitters from synaptosomes. European Journal of Pharmacology. 25:1974;411-414.
22. Román S., Vivas N.M., Badia A., Clos M.V. Interaction of a new potent anticholinesterasic compound, (±)Huprine X with muscarinic receptors in rat brain. Neuroscience letters. 325:2002;103-106.
23. Ros E., Aleu J., Gómez de Aranda I., Cantí C., Pang Y.P., Marsal J., Solsona C. Effects of bis(7)-tacrine on spontaneous synaptic activity and on the nicotinic ACh receptor of Torpedo electric organ. Journal of Neurophysiology. 86:2001;183-189.
24. Schöder H., Wevers A. Nicotinic acetylcholine receptors in Alzheimer's disease. Alzheimer's Disease Reviews. 3:1998;20-27.
25. Schrattenholz A., Pereira E.F., Roth U., Weber K.H., Albuquerque E.X., Maelicke A. Agonist responses of neural nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Molecular Pharmacology. 49:1996;1-6.
26. Storch A., Schrattenholz A., Cooper J.C., Abdel Ghani M., Gutbrod O., Weber K.H., Reinhart S., Lobbron C., Hermsen B., Soskiç V., Pereira E.F., Albuquerque E.X., Methfessel C., Maelicke A. Physostigmine, galanthamine and codeine act as "noncompetitive nicotinic receptor agonists" on clonal rat pheochromocytoma cells. European Journal of Pharmacology. 290:1995;207-219.
27. Tang X.C., Han Y.F. Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb. CNS Drug Reviews. 5:1999;281-300.
28. Wachtel R.E. Physostigmine block of ion channels activated by acetylcholine in BC3H1 cells. Molecular Pharmacology. 44:1993;1051-1055.
29. Woodruff-Pak D.S., Santos I.S. Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease. Behavior Brain Research. 113:2000;11-19.
30. Zwart R., van Kleef R. Physostigmine and atropine potentiate and inhibit neuronal α4β4 nicotinic receptors. Annals of the New York Academy of Sciences. 886:1999;636-839.
31. Zwart R., Vijverberg H. Potentiation and inhibition of neuronal nicotinic receptors by atropine: competitive and no competitive effects. Molecular Pharmacology. 52:1997;886-895.
32. Zwart R., Vijverberg H. Potentiation and inhibition of neural α4β2 nicotinic acetylcholine receptors by choline. European Journal of Pharmacology. 393:2000;209-214.